Colorectal cancer screening: Assessment of CEACAM6, LGALS4, TSPAN8 and COL1A2 as blood markers in faecal immunochemical test negative subjects
- PMID: 32257432
- PMCID: PMC7113625
- DOI: 10.1016/j.jare.2020.03.001
Colorectal cancer screening: Assessment of CEACAM6, LGALS4, TSPAN8 and COL1A2 as blood markers in faecal immunochemical test negative subjects
Abstract
Prevention is essential to reduce Colorectal Cancer (CRC) mortality. We previously reported a panel of four genes: CEACAM6, LGALS4, TSPAN8, COL1A2 (CELTiC) able to discriminate patients with CRC. Here, we assessed the CELTiC panel by quantitative polymerase chain reaction, in the blood of 174 healthy subjects, who resulted negative to the faecal immunochemical test (FITN). Using non-parametric statistic and multinomial logistic models, the FITN were compared to previously analysed subjects: 36 false positive FIT (NFIT), who were negative at colonoscopy, 36 patients with low risk lesions (LR) and 92 patients with high risk lesions or CRC (HR/CRC). FITN showed a significantly lower expression of the four genes when compared to HR/CRC. Moreover, FITN showed a significantly lower expression of TSPAN8 and COL1A2 compared to NFIT and LR patients. The multinomial logistic model confirmed that TSPAN8 alone specifically discriminated FITN from NFIT, LR and HR/CRC, while LGALS4 was able to differentiate FITN from false positive FIT. Finally, ROC curves analysis of the comparisons between FITN and HR/CRC, LR or NFIT reported AUC greater than 0.87, with a sensitivity and specificity of 83% and 76%, respectively. The CELTiC panel was confirmed a useful tool to identify CRC patients and to discriminate false FIT positive subjects.
Keywords: Blood mRNA; CEACAM6; COL1A2; Faecal immunochemical test; LGALS4; TSPAN8.
© 2020 THE AUTHORS. Published by Elsevier BV on behalf of Cairo University.
Figures





Similar articles
-
LGALS4, CEACAM6, TSPAN8, and COL1A2: Blood Markers for Colorectal Cancer-Validation in a Cohort of Subjects With Positive Fecal Immunochemical Test Result.Clin Colorectal Cancer. 2018 Jun;17(2):e217-e228. doi: 10.1016/j.clcc.2017.12.002. Epub 2017 Dec 12. Clin Colorectal Cancer. 2018. PMID: 29352642
-
Diagnostic Accuracy of an Add-On, Blood-Based Screening Test for Colorectal Cancer in Two Established Screening Programmes.Aliment Pharmacol Ther. 2025 Jun;61(12):1935-1943. doi: 10.1111/apt.70141. Epub 2025 Apr 10. Aliment Pharmacol Ther. 2025. PMID: 40207404 Free PMC article. Clinical Trial.
-
Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection.Oncotarget. 2016 May 24;7(21):30295-306. doi: 10.18632/oncotarget.8108. Oncotarget. 2016. PMID: 26993598 Free PMC article.
-
Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.Am J Gastroenterol. 2018 Dec;113(12):1778-1787. doi: 10.1038/s41395-018-0212-7. Epub 2018 Aug 29. Am J Gastroenterol. 2018. PMID: 30158713 Free PMC article.
-
Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.Gut. 2015 Aug;64(8):1327-37. doi: 10.1136/gutjnl-2014-308074. Epub 2015 Jun 3. Gut. 2015. PMID: 26041750 Review.
Cited by
-
Phenotypicand Genotypic Characterization of Clinical Isolates of Intracellular Adherent-Invasive Escherichia coli Among Different Stages, Family History, and Treated Colorectal Cancer Patients in Iran.Front Cell Infect Microbiol. 2022 Jul 11;12:938477. doi: 10.3389/fcimb.2022.938477. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35899040 Free PMC article.
-
The Roadmap of Colorectal Cancer Screening.Cancers (Basel). 2021 Mar 4;13(5):1101. doi: 10.3390/cancers13051101. Cancers (Basel). 2021. PMID: 33806465 Free PMC article. Review.
-
Targeted Nursing Combined with Endoscopic Submucosal Injection of Carbon Nanoparticles in the Treatment of Colorectal Cancer.Evid Based Complement Alternat Med. 2022 May 31;2022:8663645. doi: 10.1155/2022/8663645. eCollection 2022. Evid Based Complement Alternat Med. 2022. Retraction in: Evid Based Complement Alternat Med. 2023 Jun 21;2023:9871905. doi: 10.1155/2023/9871905. PMID: 35685723 Free PMC article. Retracted.
-
The emerging roles of CEACAM6 in human cancer (Review).Int J Oncol. 2024 Mar;64(3):27. doi: 10.3892/ijo.2024.5615. Epub 2024 Jan 19. Int J Oncol. 2024. PMID: 38240103 Free PMC article. Review.
-
Immune infiltration and prognostic and diagnostic use of LGALS4 in colon adenocarcinoma and bladder urothelial carcinoma.Am J Transl Res. 2021 Oct 15;13(10):11353-11363. eCollection 2021. Am J Transl Res. 2021. PMID: 34786063 Free PMC article.
References
-
- Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. - PubMed
-
- Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
-
- Senore C., Basu P., Anttila A., Ponti A., Tomatis M., Vale D.B. Status of implementation and organization of cancer screening in The European Union Member States—Summary results from the second European screening report. Int J Cancer. 2018;142:44–56. - PubMed
-
- Benson V.S., Atkin W.S., Green J., Nadel M.R., Patnick J., Smith R.A. Toward standardizing and reporting colorectal cancer screening indicators on an international level: the international colorectal cancer screening network. Int J Cancer. 2012;130:2961–2973. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous